<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4308">
  <stage>Registered</stage>
  <submitdate>16/02/2014</submitdate>
  <approvaldate>16/02/2014</approvaldate>
  <nctid>NCT02065999</nctid>
  <trial_identification>
    <studytitle>Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients</studytitle>
    <scientifictitle>Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients</scientifictitle>
    <utrn />
    <trialacronym>SEARCH-C</trialacronym>
    <secondaryid>VHCRP1107</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Hepatitis C Infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions />
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Prevalence of HCV resistance associated variants (RAVs) and the incidence of RAVs arising during therapy. - Descriptive statistics will be used to describe RAVs using standard international nomenclature and presented in table form. Baseline clinical and demographic data on subjects will be presented, as will rates of treatment failure and reasons for failure.</outcome>
      <timepoint>Baseline</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Factors associated with treatment failure due to virological breakthrough / relapse. - Multivariable logistic regression modelling with backwards elimination will be used to identify factors associated with this.</outcome>
      <timepoint>Baseline</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Chronic hepatitis C infection

          -  Commencing or expected to commence DAA-based HCV treatment within the next year

          -  IFN treatment-na√Øve or IFN treatment-experienced

          -  Provision of written, informed consent</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  In the opinion of the investigator that the patient is not able to provide informed
             consent

          -  Inability or unwillingness to comply with study collection requirements</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/03/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>St Vincent's Hospital - Sydney</hospital>
    <hospital>St Vincent's Hospital - Melbourne</hospital>
    <postcode>2010 - Sydney</postcode>
    <postcode>3065 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Kirby Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>The University of New South Wales</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Merck Sharp &amp; Dohme Corp.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a multi-centre prospective longitudinal cohort study with the aim of collecting and
      storing clinical data, patient blood, DNA and PBMCs to examine outcomes related to drug
      resistance, drug monitoring and host genetics in the era of directly acting antiviral drugs
      for hepatitis C therapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02065999</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gail Dr Matthews, MBChB, MRCP (UK), FRACP, PhD</name>
      <address>The University of New South Wales</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Amanda Erratt</name>
      <address />
      <phone>+61 2 9385 0882</phone>
      <fax />
      <email>aerratt@kirby.unsw.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>